Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.20 USD
Change Today +0.01 / 5.41%
Volume 401.2K
HEB On Other Exchanges
As of 8:04 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Thomas K. Equels Esq.

Executive Vice Chairman, Chief Financial Officer, General Counsel, Secretary, Member of Executive Committee, Member of Disclosure Controls Committee and Member of Strategic Planning Committee, Hemispherx Biopharma, Inc.
AgeTotal Calculated CompensationThis person is connected to 6 board members in 1 different organizations across 1 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. Thomas K. Equels, also known as Tom, Esq. serves as the President and Managing Director of Equels Law Firm. Mr. Equels has been the Chief Financial Officer of Hemispherx Biopharma, Inc. since December 4, 2013. He has been a General Counsel and Secretary of Hemispherx Biopharma, Inc. since January 1, 2010 and April 2009 respectively. He has been Litigation Counsel of Hemispherx Biopharma Inc., in a number of complex cases over ten years. He served as Managing Director ...

Read Full Background

Corporate Headquarters*

One Penn Center
Philadelphia, Pennsylvania 19103

United States

Phone: 215-988-0080
Fax: 215-988-1739

Board Members Memberships*

Executive Vice Chairman, Chief Financial Officer, General Counsel, Secretary, Member of Executive Committee, Member of Disclosure Controls Committee and Member of Strategic Planning Committee


Unknown/Other Education
Troy University
Master's Degree
Troy University
Florida State University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$1,311,801

Stock Options*

All Other Compensation$104,987
Exercisable Options1,450,000
Unexercisable Options300,000
Total Number of Options1,750,000

Total Compensation*

Total Annual Cash Compensation$1,599,250
Total Short Term Compensation$1,311,801
Other Long Term Compensation$104,987
Total Calculated Compensation$1,668,449
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HEB:US $0.20 USD +0.01


Frank Mathias Chief Executive Officer and Member of Executive Board
MediGene AG
Brenton L. Saunders J.D.Chief Executive Officer, President and Director
Allergan plc
Robert L. Parkinson Jr.Chairman, Chief Executive Officer and President
Baxter International Inc.
Pascal Soriot Chief Executive Officer, Executive Director and Member of Disclosure Committee
AstraZeneca PLC
3.1M GBP
Edward M. Kaye M.D., Ph.D.Interim Chief Executive Officer, Chief Medical Officer and Senior Vice President
Sarepta Therapeutics, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEMISPHERX BIOPHARMA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at